Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd (AKUMS) last reported results for the quarter ended Jun 2026, with sales of ₹1,167 crore and net profit of ₹101 crore. The stock last traded at ₹813, a market capitalisation of ₹12,792 crore, on a P/E of 41.9. Over the past 52 weeks the stock has ranged between ₹409 and ₹839. Figures are as of 6 Oct 2026 and are not real time.
Akums Drugs and Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹813
- Market cap
- ₹12,792 cr
- Stock P/E
- 41.9
- Book value
- ₹211
- ROE
- 8.45%
- ROCE
- 14.9%
- Dividend yield
- 0.12%
- 52w high / low
- 839/409
Metrics as of 6 Oct 2026. Not real time.
Track Akums Drugs and Pharmaceuticals Ltd
Cruxal reads every Akums Drugs and Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Akums Drugs and Pharmaceuticals Ltd growth and returns
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 6%
- TTM
- 9%
- 10 Years
- 16%
- 5 Years
- 16%
- 3 Years
- 29%
- TTM
- -7%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 82%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 10%
- Last Year
- 8%
Akums Drugs and Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,167 cr, up 14.0% from ₹1,024 cr a year earlier. Net profit was ₹101 cr, up 55.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating profit | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other income | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net profit | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS (₹) | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Akums Drugs and Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Operating profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8% | 9% | 7% | 9% | -2.4% | 8% | 3.0% | 11% | 12% | 13% |
| Net profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS (₹) | 366.55 | 523.23 | 335.61 | 943.49 | -35.30 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
TTM is the trailing twelve months to the most recent quarter.
Akums Drugs and Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other liabilities | 293 | 318 | 1,140 | 1,137 | 2,033 | 1,905 | 2,229 | 960 | 1,958 |
| Total liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Fixed assets | 444 | 501 | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,535 | 3,796 |
| Total assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
As reported by the company. Total assets equal total liabilities by construction.
Akums Drugs and Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Cash from investing | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Cash from financing | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net cash flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Free cash flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
| CFO / operating profit | 72% | 98% | 44% | 74% | -98% | 93% | 455% | 118% | 243% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Akums Drugs and Pharmaceuticals Ltd operating ratios
| Per year | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 14% | — | 20% | -16% | 22% | 2% | 16% | 15% |
| Debtor days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 | 67 |
| Inventory days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 | 110 |
| Days payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash conversion cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 | 89 |
| Working capital days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Akums Drugs and Pharmaceuticals Ltd shareholding pattern
Promoters held 75.26% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.91% and DIIs 13.44%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FIIs | 7.34% | 6.36% | 5.77% | 4.24% | 2.27% | 1.14% | 1.38% | 1.91% |
| DIIs | 7.53% | 6.99% | 7.39% | 8.85% | 9.28% | 14.41% | 14.36% | 13.44% |
| Public | 7.14% | 8.64% | 8.84% | 8.92% | 10.46% | 6.45% | 6.29% | 6.67% |
| No. of shareholders | 57,531 | 68,410 | 69,366 | 69,424 | 75,365 | 76,869 | 72,589 | 70,289 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Akums Drugs and Pharmaceuticals Ltd corporate filings
- Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018Company Updatelow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- Akums Drugs and Pharmaceuticals Ltd schedules institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding upcoming meetings…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding a scheduled…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd receives ESG ratingCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has provided an intimation regarding its ESG rating…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding a scheduled…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd schedules investor/analyst meeting for August 25, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited has issued a formal update regarding the schedule…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd schedules investor/analyst meetingCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has issued an intimation regarding a scheduled…
Read the full analysis - Akums Drugs & Pharmaceuticals Reports Strong Q1 FY27 Performance with 56% PAT Growth and Robust CDMO ExpansionCompany Updatehigh impact
Cruxal's analysis: Akums Drugs & Pharmaceuticals Limited delivered a strong Q1 FY27 performance, with…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd schedules investor and analyst meeting for August 14, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has announced an intimation for an upcoming investor…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd releases audio recording of investor/analyst conference callCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has filed the audio recording link for its recent…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd publishes routine newspaper noticeCompany Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has released a standard newspaper publication as part…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd releases Monitoring Agency Report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Ltd has filed its Monitoring Agency Report for the…
Read the full analysis - Akums Drugs and Pharmaceuticals Reports Strong Q1 FY27 Results with 56.1% PAT Growth and Strategic Acquisition of Oriflame India's Manufacturing BusinessCompany Updatehigh impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited delivered a robust performance for Q1 FY27…
Read the full analysis - Akums Drugs and Pharmaceuticals Ltd: Press Release FilingCompany Updatelow impact
Cruxal's analysis: The company has filed a press release on August 8, 2026. The disclosure is a routine…
Read the full analysis - Akums Drugs and Pharmaceuticals Q1 FY27 Consolidated PAT Rises to 101 crore; Full Utilization of IPO Proceeds ConfirmedBoard Meetinghigh impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited reported strong Q1 FY27 consolidated financial…
Read the full analysis - Akums Drugs & Pharmaceuticals Schedules Q1 FY27 Earnings Conference Call for August 10, 2026Company Updatelow impact
Cruxal's analysis: Akums Drugs & Pharmaceuticals Limited has formally announced an investor and analyst…
Read the full analysis - Akums Drugs and Pharmaceuticals Limited schedules Board Meeting for August 8, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Akums Drugs and Pharmaceuticals Limited has formally intimated the stock exchanges…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.